Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARATALL-VHR in very high-risk adult T-lineage acute lymphoblastic leukemia
2024-511627-34-00Phase 2Authorised
- Sponsor
- GIMEMA
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in acute lymphoblastic leukemia (ALL) and mixed phenotype acute leukemia (MPAL), sponsored by GIMEMA. Primary endpoint: MRD negativity after induction. Planned start Oct 2024; status: authorised.
02
Drugs
daratumumab
03
Conditions
acute lymphoblastic leukemia (ALL)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on 2024-511627-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511627-34-00.